Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: Importance of genetic testing in the entire family

被引:26
作者
Garcia-Garcia, Ana-Barbara [1 ,2 ]
Ivorra, Carmen [1 ]
Martinez-Hervas, Sergio [1 ,2 ,3 ]
Blesa, Sebastian [1 ,2 ]
Jose Fuentes, M. [1 ,4 ]
Puig, Oscar [5 ]
Javier Martin-de-Llano, Jose [6 ]
Carmena, Rafael [2 ,3 ]
Real, Jose T. [2 ,3 ]
Javier Chaves, Felipe [1 ,2 ]
机构
[1] Clin Univ Valencia, Fdn Invest Hosp, Unidad Genotipado & Diagnost Genet, E-46010 Valencia, Spain
[2] CIBERDEM, Barcelona, Spain
[3] Hosp Clin Univ Valencia, Serv Endocrinol & Nutr, Valencia 46010, Spain
[4] Univ Valencia, Dept Med, Valencia 46010, Spain
[5] Fdn Valenciana Invest Biomed, Inst Invest Citol, Valencia 46010, Spain
[6] Consorcio Hosp Gen Univ Valencia, Dept Pediat, Lab Pediat Cardiovasc Risk Unit, Valencia 46014, Spain
关键词
Autosomal dominant hypercholesterolemia; Familial hypercholesterolemia; Apolipoprotein B 100; Familial ligand defective; Mutation screening; Genetic diagnosis; LDL-RECEPTOR GENE; SEQUENCE VARIATIONS; SPANISH POPULATION; LIPID PROFILE; MUTATION; LOCUS; PCSK9; IDENTIFICATION; CHOLESTEROL; EXPRESSION;
D O I
10.1016/j.atherosclerosis.2011.07.106
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Autosomal dominant hypercholesterolemias (ADHs) are characterised by increased plasma levels of total and LDL cholesterol, predisposing to premature atherosclerosis. ADHs comprise several diseases with undistinguishable phenotype, caused by mutations in different genes: LDLR, APOB and PCSK9. Genetic studies are usually performed in patients with altered cholesterol levels. However, some persons carrying pathogenic mutations are normocholesterolemic and there are no further studies about this subject. We have studied the frequency of families and individuals carrying ADH mutations who do not present the disease in Spanish population. Methods: We have analysed genes known to cause ADH by direct sequencing in 24 ADH families (215 members). Functional effect of some LDLR gene mutations was assessed by transfecting cultured cells with plasmids. Results: Six families with mutations presented 7 mutation carriers who did not show ADH phenotype: 30% of ADH families presented normocholesterolemic individuals, and 7% of carriers of pathogenic mutations did not show ADH phenotype. We have analysed the effect of some of these mutations and they are responsible for impaired LDL receptor function. We have excluded mutations in APOB and PCSK9 genes that could reduce LDLc levels. Conclusions: An important percentage of ADH families presented individuals who do not show an ADH phenotype, but who are able to transmit the pathogenic mutation to their offspring. Genetic study of all subjects in ADH families should be performed in order to identify normocholesterolemic carriers that allow the detection of mutations in their descendants and the prevention of the disease consequences. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:423 / 430
页数:8
相关论文
共 30 条
[1]
Allard Delphine, 2005, Hum Mutat, V26, P497, DOI 10.1002/humu.9383
[2]
[Anonymous], 1997, FEMALE GENITAL MUTIL, P1
[3]
A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia [J].
Blesa, Sebastian ;
Vernia, Santiago ;
Garcia-Garcia, Ana-Barbara ;
Martinez-Hervas, Sergio ;
Ivorra, Carmen ;
Gonzalez-Albert, Veronica ;
Francisco Ascaso, Juan ;
Carlos Martin-Escudero, Juan ;
Tomas Real, Jose ;
Carmena, Rafael ;
Casado, Marta ;
Javier Chaves, Felipe .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (09) :3577-3583
[4]
Analysis of sequence variations in the LDL receptor gene in Spain: General gene screening or search for specific alterations? [J].
Blesa, Sebastian ;
Garcia-Garcia, Ana Barbara ;
Martinez-Hervas, Sergio ;
Mansego, Maria Luisa ;
Gonzalez-Albert, Veronica ;
Ascaso, Juan Francisco ;
Carmena, Rafael ;
Real, Jose Tomas ;
Chaves, Felipe Javier .
CLINICAL CHEMISTRY, 2006, 52 (06) :1021-1025
[5]
A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22 [J].
Cenarro, A. ;
Garcia-Otin, A-L ;
Tejedor, M. T. ;
Solanas, M. ;
Jarauta, E. ;
Junquera, C. ;
Ros, E. ;
Mozas, P. ;
Puzo, J. ;
Pocovi, M. ;
Civeira, F. .
CLINICAL GENETICS, 2011, 79 (05) :475-481
[6]
Large rearrangements of the LDL receptor gene and lipid profile in a FH Spanish population [J].
Chaves, FJ ;
Real, JT ;
García-García, AB ;
Puig, O ;
Ordovas, JM ;
Ascaso, JF ;
Carmena, R ;
Armengod, ME .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2001, 31 (04) :309-317
[7]
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].
Cohen, JC ;
Boerwinkle, E ;
Mosley, TH ;
Hobbs, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272
[8]
Influence of β0-thalassemia on the phenotypic expression of heterozygous familial hypercholesterolemia -: A study of patients with familial hypercholesterolemia from Sardinia [J].
Deiana, L ;
Garuti, R ;
Pes, GM ;
Carru, C ;
Errigo, A ;
Rolleri, M ;
Pisciotta, L ;
Masturzo, P ;
Cantafora, A ;
Calandra, S ;
Bertolini, S .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (01) :236-243
[9]
DELLANO JJM, 1996, ANAL BIOCHEM, V243, P210
[10]
An individual with a healthy phenotype in spite of a pathogenic LDL receptor mutation (C240F) [J].
Ekström, U ;
Abrahamson, M ;
Florén, CH ;
Tollig, H ;
Wettrell, G ;
Nilsson, E ;
Sun, XM ;
Soutar, AK ;
Nilsson-Ehle, P .
CLINICAL GENETICS, 1999, 55 (05) :332-339